| Ashley V Hooks, CRNP | |
|
824 Main St Ste 307, Phoenixville, PA 19460-4478 | |
| (610) 482-6500 | |
| Not Available |
| Full Name | Ashley V Hooks |
|---|---|
| Gender | Female |
| Speciality | Nurse Practitioner |
| Experience | 7 Years |
| Location | 824 Main St Ste 307, Phoenixville, Pennsylvania |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1518469832 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207Q00000X | Family Medicine | SP018478 (Pennsylvania) | Secondary |
| 363LF0000X | Nurse Practitioner - Family | SP018478 (Pennsylvania) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Hospital Of Univ Of Pennsylvania | Philadelphia, PA | Hospital |
| Phoenixville Hospital | Phoenixville, PA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Clinical Care Associates Of The University Of Pennsylvania Health | 4688588866 | 517 |
News Archive
LivaNova, PLC, a global medical technology company, announced today the first implant of the Perceval sutureless valve in the PERSIST-AVR trial at CHU Brabois, University of Lorraine, Nancy, France.
VIVUS, Inc. (Nasdaq: VVUS) today announced positive results from two final, phase 3 pivotal 56-week studies, EQUIP (OB-302) and CONQUER (OB-303), evaluating the safety and efficacy of Qnexa(TM), an investigational drug, in more than 3,750 patients across 93 sites. The EQUIP and CONQUER studies met all primary endpoints by demonstrating statistically significant weight loss with all three doses of Qnexa, as compared to placebo.
A study of ten years of patient outcomes shows that surgery is not only effective, but the preferred treatment for select epilepsy patients. In the most comprehensive study of long-term surgery success rates, Mayo Clinic physicians report that 73 percent of 491 Mayo Clinic patients were either seizure-free or experienced seizures only when medication was discontinued.
A team of scientists from a number of institutions around the world, including Baylor College of Medicine, has discovered that rare neurological syndromes for which there was no cause can be the result of variations in the gene ATAD3A.
Topical application of the chemotherapy medication fluorouracil appears to reduce potentially precancerous skin patches and improve the appearance of sun-damaged skin, according to a report in the June issue of Archives of Dermatology.
› Verified 3 days ago
| Entity Name | Clinical Care Associates Of The University Of Pennsylvania Health |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1972682995 PECOS PAC ID: 4688588866 Enrollment ID: O20031113000301 |
News Archive
LivaNova, PLC, a global medical technology company, announced today the first implant of the Perceval sutureless valve in the PERSIST-AVR trial at CHU Brabois, University of Lorraine, Nancy, France.
VIVUS, Inc. (Nasdaq: VVUS) today announced positive results from two final, phase 3 pivotal 56-week studies, EQUIP (OB-302) and CONQUER (OB-303), evaluating the safety and efficacy of Qnexa(TM), an investigational drug, in more than 3,750 patients across 93 sites. The EQUIP and CONQUER studies met all primary endpoints by demonstrating statistically significant weight loss with all three doses of Qnexa, as compared to placebo.
A study of ten years of patient outcomes shows that surgery is not only effective, but the preferred treatment for select epilepsy patients. In the most comprehensive study of long-term surgery success rates, Mayo Clinic physicians report that 73 percent of 491 Mayo Clinic patients were either seizure-free or experienced seizures only when medication was discontinued.
A team of scientists from a number of institutions around the world, including Baylor College of Medicine, has discovered that rare neurological syndromes for which there was no cause can be the result of variations in the gene ATAD3A.
Topical application of the chemotherapy medication fluorouracil appears to reduce potentially precancerous skin patches and improve the appearance of sun-damaged skin, according to a report in the June issue of Archives of Dermatology.
› Verified 3 days ago
| Entity Name | Penn Medicine-pma |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1144895970 PECOS PAC ID: 6507269370 Enrollment ID: O20210730002445 |
News Archive
LivaNova, PLC, a global medical technology company, announced today the first implant of the Perceval sutureless valve in the PERSIST-AVR trial at CHU Brabois, University of Lorraine, Nancy, France.
VIVUS, Inc. (Nasdaq: VVUS) today announced positive results from two final, phase 3 pivotal 56-week studies, EQUIP (OB-302) and CONQUER (OB-303), evaluating the safety and efficacy of Qnexa(TM), an investigational drug, in more than 3,750 patients across 93 sites. The EQUIP and CONQUER studies met all primary endpoints by demonstrating statistically significant weight loss with all three doses of Qnexa, as compared to placebo.
A study of ten years of patient outcomes shows that surgery is not only effective, but the preferred treatment for select epilepsy patients. In the most comprehensive study of long-term surgery success rates, Mayo Clinic physicians report that 73 percent of 491 Mayo Clinic patients were either seizure-free or experienced seizures only when medication was discontinued.
A team of scientists from a number of institutions around the world, including Baylor College of Medicine, has discovered that rare neurological syndromes for which there was no cause can be the result of variations in the gene ATAD3A.
Topical application of the chemotherapy medication fluorouracil appears to reduce potentially precancerous skin patches and improve the appearance of sun-damaged skin, according to a report in the June issue of Archives of Dermatology.
› Verified 3 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Ashley V Hooks, CRNP 2134 Fernon St, Philadelphia, PA 19145-1303 Ph: (215) 767-1062 | Ashley V Hooks, CRNP 824 Main St Ste 307, Phoenixville, PA 19460-4478 Ph: (610) 482-6500 |
News Archive
LivaNova, PLC, a global medical technology company, announced today the first implant of the Perceval sutureless valve in the PERSIST-AVR trial at CHU Brabois, University of Lorraine, Nancy, France.
VIVUS, Inc. (Nasdaq: VVUS) today announced positive results from two final, phase 3 pivotal 56-week studies, EQUIP (OB-302) and CONQUER (OB-303), evaluating the safety and efficacy of Qnexa(TM), an investigational drug, in more than 3,750 patients across 93 sites. The EQUIP and CONQUER studies met all primary endpoints by demonstrating statistically significant weight loss with all three doses of Qnexa, as compared to placebo.
A study of ten years of patient outcomes shows that surgery is not only effective, but the preferred treatment for select epilepsy patients. In the most comprehensive study of long-term surgery success rates, Mayo Clinic physicians report that 73 percent of 491 Mayo Clinic patients were either seizure-free or experienced seizures only when medication was discontinued.
A team of scientists from a number of institutions around the world, including Baylor College of Medicine, has discovered that rare neurological syndromes for which there was no cause can be the result of variations in the gene ATAD3A.
Topical application of the chemotherapy medication fluorouracil appears to reduce potentially precancerous skin patches and improve the appearance of sun-damaged skin, according to a report in the June issue of Archives of Dermatology.
› Verified 3 days ago